Stock Price Forecast

Aug. 12, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Epizyme Inc chart...

About the Company

Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..

CEO

Robert Bazemore

Exchange

NASDAQ

Website

www.epizyme.com

$53M

Total Revenue

304

Employees

$248M

Market Capitalization

-0.68

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $EPZM News

Ipsen beefs up in oncology, buying US biopharma Epizyme

1y ago, source: pharmaphorum

The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its cancer therapy Tazverik, in a deal valued at a little under $250 million. Ipsen is ...

MPM Asset Management Investors BV4 LLC's Net Worth

19d ago, source: Benzinga.com

Who is MPM Asset Management Investors BV4 LLC? MPM Asset Management Investors BV4 LLC has an estimated net worth of $148 Million. This is based on reported shares across multiple companies, which ...

Sweet Baby Inc. Doesn’t Do What Some Gamers Think It Does

22d ago, source: Kotaku

Sweet Baby Inc. is not the largest narrative design company in the games industry. Nor is it solely responsible for the characters and stories in recent high-profile releases like Alan Wake 2 ...

Did The Texas ESG Ban Have Any Bite?

1y ago, source: Forbes

Opinions expressed by Forbes Contributors are their own. I am the Kester and Brynes Professor at Columbia Business School and a Chazen Senior Scholar at the Jerome A. Chazen Institute for Global ...

MPM BioVentures IV GP LLC's Net Worth

1mon ago, source: Benzinga.com

Who is MPM BioVentures IV GP LLC? MPM BioVentures IV GP LLC has an estimated net worth of $148 Million. This is based on reported shares across multiple companies, which include Radius Health, Inc ...

Beasley Broadcast Group, Inc. (BBGI)

1d ago, source: Yahoo Finance

Beasley Broadcast Group, Inc. ( NASDAQ:BBGI ) shareholders are probably feeling a little disappointed, since its shares... Simply Wall St. Beasley Broadcast Group Full Year 2023 Earnings ...

Welcome to Inc.'s Directory of B2B Excellence

5mon ago, source: Inc

They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.

STIHL Inc.

7mon ago, source: Forbes

This company has paid to receive expanded profile features. About STIHL Inc. Virginia-based STIHL Inc. is the U.S. affiliate for the global STIHL group and the manufacturer of the number one ...

Snap Inc Class A

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Apple Inc.

11mon ago, source: Wall Street Journal

No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

About Inc.com | Everything You Need to Know to Grow and Start Your Business

12y ago, source: Inc

Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...

Snap Inc.

1mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...